Elsevier

Journal of Autoimmunity

Volume 8, Issue 4, August 1995, Pages 575-586
Journal of Autoimmunity

Autoimmunity to the cell cycle-dependent centromere protein p330d/CENP-F in disorders associated with cell proliferation

https://doi.org/10.1016/0896-8411(95)90009-8Get rights and content

Abstract

p330d/CENP-F is a novel proliferation-associated and cell cycle-dependent centromere autoantigen which appears to play a very important role in mitotic progression. As an initial step in exploring the clinical and biological significance of autoantibodies to this protein, we evaluated the clinical histories of 26 patients producing these antibodies. The antibodies were detected by both indirect immunofluorescence microscopy (HF) and Western blotting. All the sera contained anti-p330d/CENP-F IgG antibodies, with an average titer by HF of 1:6,917 (range 1:160 to 1:20,480). Most of the patients had disorders associated with abnormal or increased cell proliferation at the time the anti-p330d/CENP-F antibodies were detected. These included cancers of various types (14), chronic liver disease (3), chronic rejection of renal allografts (2), and Crohn's disease (1). The average HF titer of the anti-p330d/CENP-F antibodies in the patients with cancer, 1:10,103, was significantly higher than the average titer in non-cancer patients, 1:3,200 (P=0.008). Autoimmunity to p330d/CENP-F appeared not to be associated with rheumatic diseases, in particular scleroderma, since only three of the 26 patients had rheumatic disease and the antibodies were not detected by IIF in a group of 351 patients with scleroderma and related disorders. Our findings, although retrospective and limited to a relatively small number of patients, point to the hypothesis that autoimmunity to p330d/CENP-F could be related to events involving increased or abnormal cell proliferation.

References (29)

  • E.M. Tan

    Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology

    Adv. Immunol.

    (1989)
  • E.M. Tan

    Autoantibodies in pathology and cell biology

    Cell

    (1991)
  • H. Imai et al.

    Nucleolar antigens and autoantibodies in hepatocellular carcinoma and other malignancies

    Am. J. Pathol.

    (1992)
  • P.J. Thomas et al.

    Antinuclear, antinucleolar, and anti-cytoplasmic antibodies in patients with malignant melanoma

    Cancer Res.

    (1983)
  • J. Wasserman et al.

    Autoantibodies in patients with carcinoma of the breast: correlation with prognosis

    Clin. Exp. Immunol.

    (1975)
  • K. Angelopoulou et al.

    Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers

    Int. J. Cancer

    (1994)
  • S.M. Pupa et al.

    Antibody response against the c-erbB-2 oncoprotein in breast carcinoma patients

    Cancer Res.

    (1993)
  • M.L. Disis et al.

    Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer

    Cancer Res.

    (1994)
  • K. Ben-Mahrez et al.

    Circulating antibodies against c-myc oncogene product in sera of colorectal-cancer patients

    Int. J. Cancer

    (1990)
  • K. Ben-Mahrez et al.

    Detection of circulating antibodies against c-myc protein in cancer patient sera

    Br. J. Cancer

    (1988)
  • I. Sorokine et al.

    Presence of circulating anti-c-myb oncogene product antibodies in human sera

    Int. J. Cancer

    (1991)
  • K. Miyachi et al.

    Autoantibody to a nuclear antigen in proliferating cells

    J. Immunol.

    (1978)
  • W.C. Earnshaw et al.

    Identification of a family of human centromere proteins using autoimmune sera from patients with scleroderma

    Chromosoma

    (1985)
  • R. Balczon et al.

    The identification of mammalian centrosomal antigens using autoimmune anticentrosome sera

    Cell Motil. Cytoskeleton

    (1991)
  • Cited by (53)

    • Association of serum anti-centromere protein F antibodies with clinical response to infliximab in patients with rheumatoid arthritis: A prospective study

      2020, Seminars in Arthritis and Rheumatism
      Citation Excerpt :

      Centromere proteins (CENP) are the main components of the constricted regions of chromosomes [33], which play a major role in cell proliferation, mediating chromosome movement and sister chromatid separation during mitosis [34]. Historically, individual serum CENP autoantibodies have been related to different diseases: anti-CENP-A, anti-CENP-B, anti-CENP-C and anti-CENP-E antibodies are related to limited cutaneous systemic scleroderma (lcSSc) [35-38], anti-CENP-H putatively to Sjögren's syndrome [39], and anti-CENP-F to malignancies [34,40–43]. These autoantibodies, such as other anti-nuclear antibodies (ANAs) are commonly identified by indirect immunofluorescence (IIF).

    • IV Brazilian guidelines for autoantibodies on HEp-2 cells

      2014, Revista Brasileira de Reumatologia
    • Antinuclear antibodies: A contemporary nomenclature using HEp-2 cells

      2010, Journal of Autoimmunity
      Citation Excerpt :

      Anti-midbody is most often found in patients with SSc or Raynaud’s syndrome [4,5]. This particular IIF staining pattern should be recognized with certainty since the main disease association is some form of cancer, most commonly lung and breast cancers [33]. The pattern was described like this (Fig. 20): “The most characteristic feature is seen in metaphase cells, where the pattern is constituted by 2 sets of dense large granules surrounding the chromosomal metaphase plate as a grip, often looking like a zipper.

    • Bioquiz: Anti-CENP-F (anticentromere F protein) antibodies

      2009, Revue Francophone des Laboratoires
    View all citing articles on Scopus
    View full text